{"id":511600,"date":"2021-07-12T07:03:22","date_gmt":"2021-07-12T11:03:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/"},"modified":"2021-07-12T07:03:22","modified_gmt":"2021-07-12T11:03:22","slug":"prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/","title":{"rendered":"Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars, including 100 million dollars in upfront and near-term clinical milestone payments<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">Novo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart disease ATTR cardiomyopathy<\/li>\n<\/ul>\n<p align=\"justify\">DUBLIN, Ireland and BAGSV\u00c6RD, Denmark, July  12, 2021  (GLOBE NEWSWIRE) &#8212; Prothena Corporation plc (NASDAQ:PRTA) and Novo Nordisk A\/S (Nasdaq Copenhagen: NOVO B) today announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena\u2019s clinical stage antibody PRX004 and broader ATTR amyloidosis programme.<\/p>\n<p align=\"justify\">PRX004 is a phase 2 ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associated with the disease pathology of ATTR amyloidosis.<\/p>\n<p align=\"justify\">ATTR amyloidosis is a rare, progressive, and fatal disease characterised by the abnormal buildup of amyloid deposits composed of misfolded transthyretin protein in organs and tissues, most commonly the heart and\/or nervous system.<\/p>\n<p align=\"justify\">Prothena has completed a phase 1 study with PRX004 in patients with hereditary forms of ATTR, in which PRX004 was found to be safe and well tolerated.<\/p>\n<p align=\"justify\">Novo Nordisk will initially focus on the clinical development of PRX004 in ATTR cardiomyopathy &#8211; an underdiagnosed and potentially fatal form of ATTR amyloidosis characterised by build-up of amyloid deposits in cardiac tissue.<\/p>\n<p align=\"justify\">Under the terms of the definitive purchase agreement, Novo Nordisk acquires Prothena\u2019s wholly-owned subsidiary and gains full worldwide rights to the intellectual property and related rights of Prothena\u2019s ATTR amyloidosis business and pipeline. Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars including 100 million dollars in upfront and near-term clinical milestone payments.<\/p>\n<p align=\"justify\">\u201cToday\u2019s announcement is consistent with our commitment to create a better future for patients in critical need of new treatment options. We are confident that Novo Nordisk will leverage its extensive expertise in developing treatments for those affected by cardiovascular diseases to advance this promising potential treatment to patients on an expedited timeline,\u201d said Hideki Garren, MD, PhD, chief medical officer of Prothena. \u201cWith Novo Nordisk\u2019s commitment to further develop PRX004 in ATTR cardiomyopathy, Prothena will continue to focus on our mission to advance our robust portfolio designed to address rare peripheral amyloid and neurodegenerative diseases. We also wish to extend our sincere thanks and appreciation to all the patients and investigators who participated in the PRX004 phase 1 study.\u201d<\/p>\n<p align=\"justify\">\u201cWith its innovative amyloid-depleting mechanism, PRX004 has the potential to offer a novel treatment option for ATTR cardiomyopathy \u2013 an often fatal disease with significant unmet medical need,\u201d said Marcus Schindler, chief scientific officer, EVP Research and Early Development at Novo Nordisk. \u201cThis acquisition is a testament to Prothena\u2019s pioneering work in ATTR amyloidosis and Novo Nordisk\u2019s dedication to advancing new disease-modifying therapies for the benefit of people with cardiovascular diseases which are the world\u2019s leading cause of death.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About PRX004<\/strong>\n      <\/p>\n<p align=\"justify\">PRX004 is an investigational humanised monoclonal antibody designed to deplete amyloid associated with disease pathology that underlies hereditary and wild type ATTR amyloidosis (hATTR and wtATTR, respectively), without affecting the native, normal tetrameric form of the protein. It is generally accepted that at the time of diagnosis, affected organs in ATTR patients contain extracellular amyloid deposits that cause organ dysfunction. PRX004 has been shown in preclinical studies to promote clearance of insoluble amyloid fibrils through antibody-mediated phagocytosis and inhibit amyloid formation. This depleter mechanism of action has the potential to provide benefit for ATTR patients at high risk for early mortality due to amyloid deposition in vital organs.<\/p>\n<p align=\"justify\">Prothena has completed a Phase 1, open-label, multicenter dose-escalation study (NCT03336580). 21 patients with hereditary ATTR Amyloidosis (hATTR) were enrolled to receive PRX004 intravenously once every 28 days for up to 3 infusions in the dose escalation phase of the study. Patients were enrolled into 1 of the following 6 PRX004 dose cohorts: 0.1, 0.3, 1, 3, 10, and 30 mg\/kg. Eligible patients who completed dose-escalation were provided the opportunity to enrol in the long-term extension (LTE) portion of the study. All 21 patients enrolled in the Phase 1 study successfully completed dose-escalation and 17 patients were subsequently enrolled in the LTE. PRX004 was found to be safe and well tolerated across all dose levels.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Prothena<\/strong>\n      <\/p>\n<p align=\"justify\">Prothena Corporation plc is a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena\u2019s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, Alzheimer\u2019s disease, Parkinson\u2019s disease and a number of other neurodegenerative diseases. For more information, please visit the Company\u2019s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.<\/p>\n<p align=\"justify\">\n        <strong>About Novo Nordisk<\/strong>\n      <\/p>\n<p align=\"justify\">Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VZkAiVAzJgQTnLDDoYh21HOUeyxd9qWw-c40ErJ_Hyn5Xo23_eHRrLqd6XhaKv4CS-8SIzQNQYDUIwWHbvsajg==\" rel=\"nofollow noopener\" target=\"_blank\">novonordisk.com<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nTIk68rm-FDDRagL8LlIy4Ka1IK5jJDGkFbOqp-VU8tYQytnCJ2tyGUXZSpVcKPP1hSvCZdM5al2EHM5Eu4QI7EKCLHsa74JRdjYMaUg_SQ=\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w3lZ1oeCwh__tkzBn_EI7-G0v1GgwF8wNJ-RypPwKa49i6zdBw-89NY6-U-3JjH5I_QJbXKqz2NExBlXE7DDsg==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oPwP6PilnPk3L1lf3p-AXrHJ2WTddks0JOD3_8EzbHEo4hPgdS1XKHNnrCXmcgLkQ1_X1Q-Juf5JJyRf2mBgJD682B4fIcgTD5CneLvyatQ=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VU_50TZWwrYNKhAR0iXKJw7x9BvPP-nDYxem5tvY17koAB2CT9k-ykpa0E-uD_5ccL1tCDMmQrXuFC3YLqiVZg==\" rel=\"nofollow noopener\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>This press release contains forward-looking statements regarding the definitive purchase agreement and the development of PRX004, including the ability of Novo Nordisk to successfully research, develop and commercialize PRX004, the ability of Novo Nordisk to obtain regulatory approval to manufacture, market and sell the products in and outside of the United States and the ability for Novo Nordisk to achieve the requirements of the milestones set forth in the definitive purchase agreement in order for Prothena to be entitled to the milestone payments.\u00a0 These forward-looking statements involve risks and uncertainties.\u00a0 Actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to the risks and uncertainties described in Prothena\u2019s SEC filings, including the \u201cRisk Factors\u201d section of the Quarterly Report on Form 10-Q filed with the SEC on May 11, 2021.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>\n        <strong>Prothena Corporation plc Media &amp; Investors<\/strong><br \/>\n        <br \/>Jennifer Zibuda, Director, Investor Relations &amp; Communications<br \/>+1 650 837 8535, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-s1QHhv-OJUBKZG_3gesQfWuHWBGXU9k-z2zsjiglFHCSgmhsIlynxy9vday2ZOQJ3kyDMCibmHhTkvQCQBbD_I3fHentHhqOVeaLLqMr__xB4BEXC7wmAhidIJddD9L\" rel=\"nofollow noopener\" target=\"_blank\"><u>jennifer.zibuda@prothena.com<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>Novo Nordisk Media<\/strong><br \/>\n        <br \/>Martin Havtorn Petersen<br \/>+45 3075 5246, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d_zAVOUh8V7hLNUmlwpJqt41GU5V1qCdfp_RSFYIrQCU1E8QH-o4Qi_oPK9zUj1zlr62Kt15EJ0VoyqR8uYGiQaH5t-m_-6cM5lSOXsAxig=\" rel=\"nofollow noopener\" target=\"_blank\">mhpz@novonordisk.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Novo Nordisk Investors<\/strong><br \/>\n        <br \/>Daniel Muusmann Bohsen<br \/>+45 3075 2175, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uXD6U5-UV2Ut1Ojh14VahVq-YAsS8b96-Wvs_OpOkN2PPCQ8K1AjrJo5SD1-_tErNnx9BK8Y8zrfr-OPCLtB1DijMsFlH8Fy-2_cU6hhVyc=\" rel=\"nofollow noopener\" target=\"_blank\">dabo@novonordisk.com<\/a><br \/>Ann S\u00f8nderm\u00f8lle Rendb\u00e6k<br \/>+45 3075 2253, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=O9M8uY4vV-ZGyJn7WvCIosCqXzWjgJYouAbUMpt5yMy3jJLSXhMwok00R-0iXiBkcgzP7zPCt2TKn3o5MgRGIJkGfG4k34mCjjx_HrL8KK0=\" rel=\"nofollow noopener\" target=\"_blank\">arnd@novonordisk.com<\/a><br \/>David Heiberg Landsted<br \/>+45 3077 6915, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5j8cZCphSGWdg45inFA0NWOggaiTwMT3Ezl-CGZplhu1S3-s6Vvua4sfRFaY-V1avMkKzmVVgSwCQt4AKLRUBQAOLgsnCJFr4wg37Pk9508=\" rel=\"nofollow noopener\" target=\"_blank\">dhel@novonordisk.com<\/a><br \/>Mark Joseph Root<br \/>+1 848 213 3219, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kZ9zgL1-a8gyWDQIvHAXGzwj9otrDIHRNQA_u6AUO6nSa7IyJR4WSOKFlZSHSMvQDaRwdjWkGDjeerBZoLi091GhN_FLq630n3EbwUoorHI=\" rel=\"nofollow noopener\" target=\"_blank\">mjhr@novonordisk.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ3MyM0MjkxNzA0IzIwMDkwMjk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/dbf043a3-f1a0-46ef-8714-1d41a624d239\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars, including 100 million dollars in upfront and near-term clinical milestone payments Novo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart disease ATTR cardiomyopathy DUBLIN, Ireland and BAGSV\u00c6RD, Denmark, July 12, 2021 (GLOBE NEWSWIRE) &#8212; Prothena Corporation plc (NASDAQ:PRTA) and Novo Nordisk A\/S (Nasdaq Copenhagen: NOVO B) today announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena\u2019s clinical stage antibody PRX004 and broader ATTR amyloidosis programme. PRX004 is a phase 2 ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associated with the disease pathology of ATTR amyloidosis. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-511600","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars, including 100 million dollars in upfront and near-term clinical milestone payments Novo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart disease ATTR cardiomyopathy DUBLIN, Ireland and BAGSV\u00c6RD, Denmark, July 12, 2021 (GLOBE NEWSWIRE) &#8212; Prothena Corporation plc (NASDAQ:PRTA) and Novo Nordisk A\/S (Nasdaq Copenhagen: NOVO B) today announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena\u2019s clinical stage antibody PRX004 and broader ATTR amyloidosis programme. PRX004 is a phase 2 ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associated with the disease pathology of ATTR amyloidosis. &hellip; Continue reading &quot;Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-12T11:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ3MyM0MjkxNzA0IzIwMDkwMjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme\",\"datePublished\":\"2021-07-12T11:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\\\/\"},\"wordCount\":1120,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODQ3MyM0MjkxNzA0IzIwMDkwMjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\\\/\",\"name\":\"Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODQ3MyM0MjkxNzA0IzIwMDkwMjk=\",\"datePublished\":\"2021-07-12T11:03:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODQ3MyM0MjkxNzA0IzIwMDkwMjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODQ3MyM0MjkxNzA0IzIwMDkwMjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/","og_locale":"en_US","og_type":"article","og_title":"Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme - Market Newsdesk","og_description":"Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars, including 100 million dollars in upfront and near-term clinical milestone payments Novo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart disease ATTR cardiomyopathy DUBLIN, Ireland and BAGSV\u00c6RD, Denmark, July 12, 2021 (GLOBE NEWSWIRE) &#8212; Prothena Corporation plc (NASDAQ:PRTA) and Novo Nordisk A\/S (Nasdaq Copenhagen: NOVO B) today announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena\u2019s clinical stage antibody PRX004 and broader ATTR amyloidosis programme. PRX004 is a phase 2 ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associated with the disease pathology of ATTR amyloidosis. &hellip; Continue reading \"Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-12T11:03:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ3MyM0MjkxNzA0IzIwMDkwMjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme","datePublished":"2021-07-12T11:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/"},"wordCount":1120,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ3MyM0MjkxNzA0IzIwMDkwMjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/","name":"Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ3MyM0MjkxNzA0IzIwMDkwMjk=","datePublished":"2021-07-12T11:03:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ3MyM0MjkxNzA0IzIwMDkwMjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ3MyM0MjkxNzA0IzIwMDkwMjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=511600"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511600\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=511600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=511600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=511600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}